2seventybio is a clinical-stage cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. Following a strategic asset sale and restructuring in 2024, the company is concentrating its efforts on advancing its core pipeline of innovative CAR T cell therapies for hematologic malignancies, aiming to bring new hope to patients with difficult-to-treat cancers.
Serves as the primary center for corporate leadership, research and development activities, clinical operations, and strategic business development for its focused oncology pipeline.
State-of-the-art laboratory facilities, collaborative workspaces, and its strategic location within the dense Kendall Square biotech ecosystem, offering proximity to leading research institutions and industry peers.
A dynamic, science-driven, and highly collaborative environment, intensely focused on its mission to develop life-changing therapies for cancer patients. The culture emphasizes innovation, resilience, and a patient-first mindset, typical of agile biotech firms in a leading innovation district.
Strategically situated in Kendall Square, the heart of the Boston/Cambridge biotech cluster, providing unparalleled access to scientific talent, academic collaborations (e.g., MIT, Harvard-affiliated hospitals), and a vibrant network of biotech companies and investors, crucial for advancing its cell therapy programs.
Following its 2024 restructuring, 2seventybio's physical presence is primarily consolidated in Cambridge, MA. However, its global reach is maintained through clinical trial operations for its pipeline candidates, which may involve sites and patients in multiple countries. The company may also engage in international collaborations with research institutions and consider global regulatory and commercialization strategies for its therapies.
60 Binney Street
Cambridge
MA
USA
Address: 150 Second Street, Cambridge, MA 02142 (Former Site)
Formerly supported clinical and potential commercial manufacturing needs for the company's cell therapy programs in the U.S.
Address: 2001 Westlake Avenue North, Seattle, WA 98109 (Former Site)
Formerly contributed to the company's R&D pipeline and innovation, leveraging the U.S. West Coast biotech ecosystem.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, 2seventy bio' leadership includes:
2seventy bio has been backed by several prominent investors over the years, including:
Over the past 12 months, 2seventybio underwent a significant strategic restructuring, including changes in executive leadership. Key changes involved Nick Leschly transitioning to Chairman, Chip Baird becoming CEO, and the departure of former CFO Chris Krawtschuk. These changes reflect the company's sharpened focus after its asset sale to Regeneron.
Discover the tools 2seventy bio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
2seventybio likely utilizes common corporate email formats. The most probable patterns include [first initial][last name]@2seventybio.com (e.g., jdoe@2seventybio.com) and [first name].[last name]@2seventybio.com (e.g., jane.doe@2seventybio.com). For important communications, verification is recommended.
[first_initial][last]@2seventybio.com
Format
jdoe@2seventybio.com
Example
90%
Success rate
2seventybio Press Release • May 2, 2024
2seventybio announced the completion of the sale of its portfolio of discovery and clinical-stage oncology and autoimmune R&D programs to Regeneron Pharmaceuticals. The company also detailed a strategic restructuring to focus on advancing its core CAR T pipeline, primarily the bbT369 program, with a significantly reduced workforce and a new leadership team....more
2seventybio Press Release • May 2, 2024
Coinciding with its restructuring news, 2seventybio reported its Q1 2024 financial results. The report detailed its financial standing after the Regeneron deal, revised operational plans, and reaffirmed its commitment to developing its core cell therapy assets for patients with cancer....more
2seventybio Press Release • May 28, 2024
2seventybio announced its participation in the Jefferies Healthcare Conference in June 2024. This provided an early opportunity for the new leadership team to present the company's updated strategy, pipeline focus, and future outlook to the investment community following its recent transformation....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including 2seventy bio, are just a search away.